Wolf D - Search Results

1

[Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib].

Wolf D, Gastl G, Rumpold H. Wolf D, et al. Dtsch Med Wochenschr. 2004 Oct 1;129(40):2104-6. doi: 10.1055/s-2004-831852. Dtsch Med Wochenschr. 2004. PMID: 15455302 German.

2

The kinase inhibitor imatinib--an immunosuppressive drug?

Wolf D, Tilg H, Rumpold H, Gastl G, Wolf AM. Wolf D, et al. Among authors: wolf am. Curr Cancer Drug Targets. 2007 May;7(3):251-8. doi: 10.2174/156800907780618293. Curr Cancer Drug Targets. 2007. PMID: 17504122 Review.

3

Current treatment concepts of Philadelphia-negative MPN.

Wolf D, Rudzki J, Gastl G. Wolf D, et al. Curr Cancer Drug Targets. 2011 Jan;11(1):44-55. doi: 10.2174/156800911793743592. Curr Cancer Drug Targets. 2011. PMID: 21062242 Review.

4

The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation.

Wolf AM, Wolf D, Rumpold H, Ludwiczek S, Enrich B, Gastl G, Weiss G, Tilg H. Wolf AM, et al. Among authors: wolf d. Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13622-7. doi: 10.1073/pnas.0501758102. Epub 2005 Sep 8. Proc Natl Acad Sci U S A. 2005. PMID: 16174751 Free PMC article.

5

A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours.

Wolf D, Rumpold H. Wolf D, et al. Drug Saf. 2009;32(11):1001-15. doi: 10.2165/11314600-000000000-00000. Drug Saf. 2009. PMID: 19810774 Review.

6

The role of P-glycoprotein in imatinib resistance.

Rumpold H, Wolf AM, Wolf D. Rumpold H, et al. Among authors: wolf d, wolf am. Leukemia. 2006 Jan;20(1):144; author reply 144-5. doi: 10.1038/sj.leu.2404001. Leukemia. 2006. PMID: 16270042 No abstract available.

7

RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines.

Rumpold H, Wolf AM, Gruenewald K, Gastl G, Gunsilius E, Wolf D. Rumpold H, et al. Among authors: wolf d, wolf am. Exp Hematol. 2005 Jul;33(7):767-75. doi: 10.1016/j.exphem.2005.03.014. Exp Hematol. 2005. PMID: 15963852 Free article.

8

Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features.

Eisendle K, Wolf D, Gastl G, Kircher-Eibl B. Eisendle K, et al. Among authors: wolf d. Leuk Lymphoma. 2005 May;46(5):663-70. doi: 10.1080/10428190400029825. Leuk Lymphoma. 2005. PMID: 16019503 Review.

9

Telomere length of in vivo expanded CD4(+)CD25 (+) regulatory T-cells is preserved in cancer patients.

Wolf D, Rumpold H, Koppelstätter C, Gastl GA, Steurer M, Mayer G, Gunsilius E, Tilg H, Wolf AM. Wolf D, et al. Among authors: wolf am. Cancer Immunol Immunother. 2006 Oct;55(10):1198-208. doi: 10.1007/s00262-005-0107-5. Epub 2005 Dec 16. Cancer Immunol Immunother. 2006. PMID: 16362412 Free PMC article.

10

Regulatory T cells in cancer biology: a possible new target for biochemical therapies.

Wolf D, Rumpold H, Wolf AM. Wolf D, et al. Among authors: wolf am. Mini Rev Med Chem. 2006 May;6(5):509-13. doi: 10.2174/138955706776876230. Mini Rev Med Chem. 2006. PMID: 16719824 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,910 results

Search Page

Filters